CN110563551B - 一种合成反式2-烯-4-炔-1-醇类化合物的方法 - Google Patents

一种合成反式2-烯-4-炔-1-醇类化合物的方法 Download PDF

Info

Publication number
CN110563551B
CN110563551B CN201910797729.9A CN201910797729A CN110563551B CN 110563551 B CN110563551 B CN 110563551B CN 201910797729 A CN201910797729 A CN 201910797729A CN 110563551 B CN110563551 B CN 110563551B
Authority
CN
China
Prior art keywords
formula
alkyne
trans
solvent
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910797729.9A
Other languages
English (en)
Other versions
CN110563551A (zh
Inventor
刘运奎
胡晓君
周丙伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University of Technology ZJUT
Original Assignee
Zhejiang University of Technology ZJUT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University of Technology ZJUT filed Critical Zhejiang University of Technology ZJUT
Priority to CN201910797729.9A priority Critical patent/CN110563551B/zh
Publication of CN110563551A publication Critical patent/CN110563551A/zh
Application granted granted Critical
Publication of CN110563551B publication Critical patent/CN110563551B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2442Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/09Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis
    • C07C29/10Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of ethers, including cyclic ethers, e.g. oxiranes
    • C07C29/103Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of ethers, including cyclic ethers, e.g. oxiranes of cyclic ethers
    • C07C29/106Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of ethers, including cyclic ethers, e.g. oxiranes of cyclic ethers of oxiranes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/18Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/26Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/62Isoquinoline or hydrogenated isoquinoline ring systems
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/10Complexes comprising metals of Group I (IA or IB) as the central metal
    • B01J2531/18Gold

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

本发明公开了一种合成反式2‑烯‑4‑炔‑1‑醇类化合物的方法,所述的方法按照如下步骤进行制备:以式Ⅰ所示2‑丙炔基环氧乙烷为起始物,在金催化剂、四(3,5‑二(三氟甲基)苯基)硼酸钠、溶剂存在条件下,加热至80℃‑100℃反应过夜,得到反应液经分离纯化,制备得到式Ⅱ所示反式线性2‑炔‑4‑烯‑1‑醇类化合物;所述四(3,5‑二(三氟甲基)苯基)硼酸钠、金催化剂与式Ⅰ所示2‑丙炔基环氧乙烷的物质的量之比为0.05~0.1:0.02~0.05:1。本发明所述的原料及反应过程安全环保;产物的结构单一,选择性好,无异构体产生;原料易得,且对原料的构型没有特殊要求,反应步骤简单,且是一种合成反式2‑烯‑4‑炔‑1‑醇类化合物的新路线。

Description

一种合成反式2-烯-4-炔-1-醇类化合物的方法
技术领域
本发明涉及一种有机化合物的合成方法,具体地说涉及一种反式2-烯-4-炔-1-醇类化合物的制备方法。
背景技术
线性的反式烯炔化合物在生物活性化合物和天然化合物中扮演着一个重要的角色,包括oxamflatin,以及一种糖尿病治疗药物NNC 61-4655等,而且值得注意的是这些化合物的烯丙基位都是含氧官能团。2-炔-4-烯-1-醇类以及相关化合物在一些列活性物质的合成过程中是十分有用的前体。
2000年,Takeuchi,Ryo发现了一种以(E)-5-苯基戊-2-烯-4-炔酸乙酯为原料,二异丁基氢化铝为还原剂在-78℃下反应,以合成反式2-烯-4-炔-1-醇类化合物的方法(Journal of Organic Chemistry,65(5), 1558-1561;2000),但是此方法存在着所用的还原剂易燃比较危险,且原料必须是单一构型等缺点。
Figure BDA0002181440660000011
末端炔烃的选择性催化二聚反应本是形成烯炔结构的有效方法(Chem.Soc.Rev.2016,45,2212–2238),然而炔烃的二聚反应可导致形成线性的E/Z混合物或是形成了非线性产物,这取决于催化剂的选择。而且偶联两种不同的炔烃,选择性的生成空间结构单一的产物显得十分困难。2016年,Matthew G.Lauer发现了一种以钯催化苯乙炔与丙炔醇偶联生成反式2-烯-4-炔-1-醇类化合物的方法(ACS Catal. 2016,6,5834-5842),但是此方法存在着在产生目标产物的同时,会生成一定量的异构体导致难以分离,以及丙炔醇毒性较大等不足。
Figure BDA0002181440660000021
因此,开发一种简单的、通用的合成反式线性2-炔-4-烯-1-醇类化合物的方法是十分有必要的。
发明内容
针对现有技术的不足,本发明提供了一种通用,简便,高效的合成反式线性2-炔-4-烯-1-醇类化合物的方法。
本发明的技术方案是:
一种合成反式2-烯-4-炔-1-醇类化合物的方法,按照如下步骤进行制备:
以式Ⅰ所示2-丙炔基环氧乙烷为起始物,在金催化剂、四(3, 5-二(三氟甲基)苯基)硼酸钠、溶剂存在条件下,加热至80℃-100℃反应过夜,得到反应液经分离纯化,制备得到式Ⅱ所示反式线性2- 炔-4-烯-1-醇类化合物;所述四(3,5-二(三氟甲基)苯基)硼酸钠、金催化剂与式Ⅰ所示2-丙炔基环氧乙烷的物质的量之比为 0.05~0.1:0.02~0.05:1(优选为0.1:0.02:1);具体反应式如下:
Figure BDA0002181440660000031
其中,式Ⅰ或Ⅱ中,R为苯基、4-乙基苯基、2-甲基苯基、4-甲氧基苯基或3-噻吩基中的一种。
进一步,本发明所述的金催化剂如下:
Figure BDA0002181440660000032
再进一步,本发明所述的金催化剂的制备过程如下:
Figure BDA0002181440660000033
本发明所述的方法,所述的反应温度优选为90℃。
本发明所述的方法,所述溶剂为二氯乙烷、甲苯或氟苯中的一种,最优选为二氯乙烷。
本发明所述的方法,所述溶剂的最优用量以所述式Ⅰ所示2-丙炔基环氧乙烷的物质的量计为10L/mol。
本发明所述的方法,所述反应液的分离纯化为:将反应液冷却至室温后,在反应液中加入柱层析硅胶,并通过减压蒸馏除去溶剂,通过柱色谱分离,以石油醚/乙酸乙酯=5:1作为洗脱剂,收集含目标产物的洗脱液,减压蒸除溶剂得到目标产物。
进一步,所述柱层析硅胶为100-200目。
本发明所述式Ⅱ所示含N-二氟甲基类化合物优选为下列化合物之一:
Figure BDA0002181440660000041
与现有技术相比,本发明的有益效果是:
(1)原料及反应过程安全环保;
(2)产物的结构单一,选择性好,无异构体产生;
(3)原料易得,且对原料的构型没有特殊要求,反应步骤简单,且是一种合成反式2-烯-4-炔-1-醇类化合物的新路线。
具体实施方式
下面结合具体实施例对本发明作进一步详细说明,但本发明的保护范围不限于此:
实施例中所述的金催化剂的制备过程为:
A的合成:向装有磁子的三口瓶中加入5-溴异喹啉(10mmol), 2-溴苯基硼酸(1.06equiv.),四(三苯基膦)钯(5mol%),碳酸氢钠(4.5equiv.),并对其进行氮气保护,用注射器往瓶中加入20ml乙二醇二甲醚以及10ml去离子水,将体系加热至95℃反应过夜。待反应结束后,冷却至室温,用二氯甲烷萃取,收集有机相,并对水相再萃取两次,合并有机相,将有机相用水洗涤,并用无水硫酸钠干燥,随后用柱层析分离获得产物A。
B的合成:向装有磁子的圆底烧瓶中加入A(10mmol),以及30 ml四氢呋喃,室温搅拌下加入碘甲烷(1.5equiv.),反应24小时。反应结束后,有大量黄色固体析出,进行抽滤获得的固体即为目标产物。
C的合成:向装有磁子的圆底烧瓶中加入B(5mmol),以及10ml 甲醇,室温搅拌下加入硼氢化钠(3.0equiv.),反应12小时。反应结束后,向体系中加入饱和碳酸钠溶液进行淬灭,之后用二氯甲烷萃取,收集有机相,并对水相再萃取两次,合并有机相,将有机相用水洗涤,并用无水硫酸钠干燥,随后用柱层析分离获得产物C。
D的合成:向装有磁子的三口瓶中加入C(4mmol),醋酸钯(5 mol%),dippf(6mol%),叔丁醇钠(1.02equiv.),并对其进行氮气保护,用注射器往瓶中注入10mol干燥的甲苯,室温搅拌约20 分钟,待反应体系呈均相后,往体系中加入HPAd2(1.1equiv.),将体系加热至110℃反应过夜。反应结束后,冷却至室温,柱层析分离获得产物D。
表征数据:1H NMR(CDCl3,500MHz)δ:7.89(d,J=7.4Hz,1H),7.34 (pd,J=7.4,1.6Hz,2H),7.17-7.15(m,1H),7.12(t,J=7.5Hz,1H),7.00 (d,J=7.5Hz,1H),6.97(d,J=7.5Hz,1H),3.83(d,J=14.9Hz,1H), 3.56(d,J=14.9Hz,1H),2.77(dt,J=10.4,4.8Hz,1H),2.70-2.66(m, 1H),2.50–2.33(m,5H),2.03–1.80(m,18H),1.65(d,J=12.3Hz, 12H).13C NMR(CDCl3,125MHz)δ:150.12(d,J=33.9Hz),142.49(d, J=6.6Hz),136.83(d,J=2.4Hz),133.80,133.63,133.41,131.30, 130.89(d,J=6.6Hz),129.72(d,J=3.3Hz),128.11,125.29(d,J=4.6 Hz),124.18,58.20,52.82,45.79,42.03(d,J=13.1Hz),37.46(dd,J= 58.6,25.6Hz),36.93,28.87(d,J=8.5Hz),28.56.
E的合成:向装有磁子的圆底烧瓶中加入D(1.01equv.),DMS -AuCl(1mmol),以及6ml无水二氯甲烷,室温搅拌30min。反应结束后,将体系减压除去溶剂即获得产物E。
表征数据:1H NMR(CDCl3,500MHz)δ:7.86(t,J=7.3Hz,1H), 7.51(t,J=7.4Hz,1H),7.47(t,J=7.6Hz,1H),7.24–7.21 (m,1H),7.20(d,J=7.6Hz,1H),7.15(t,J=7.6Hz,1H),6.78 (d,J=7.3Hz,1H),3.83(d,J=14.9Hz,1H),3.71(d,J=14. 9Hz,1H),2.81–2.71(m,1H),2.62–2.52(m,2H),2.45(s,2 H),2.32–2.24(m,1H),2.23–1.91(m,18H),1.66(d,J=14.7 Hz,12H).13C NMR(CDCl3,125MHz)δ:149.43(d,J=13.6H z),140.88(d,J=6.1Hz),135.95,134.66(d,J=2.4Hz),133.30 (d,J=7.5Hz),131.34,130.75(d,J=2.2Hz),128.18,126.77, 126.19(d,J=6.6Hz),125.01,124.39(d,J=43.1Hz),58.16,5 2.18,45.84,42.73(dd,J=97.2,23.8Hz),42.24(dd,J=121.9, 2.2Hz),36.23(dd,J=4.3,1.4Hz),28.88,28.58(dd,J=30.8, 9.8Hz).
实施例1
Figure BDA0002181440660000071
将0.004mmol
Figure BDA0002181440660000072
0.02mmol四(3,5-二(三氟甲基) 苯基)硼酸钠加入15mlschlenck管中,氮气保护完成后,再用注射器加入0.2mmol 2-(3-苯基-2-丙炔基)环氧乙烷和2mL DCE。接着,在90℃油浴下反应12小时。反应结束后,在反应液中加入两药匙柱层析硅胶(100-200目),并通过减压蒸馏除去溶剂,再通过柱色谱分离得到产物纯品(以石油醚/乙酸乙酯=5:1作为洗脱剂)。该物质为黄色液体,产率68%。
表征数据:1H NMR(500MHz,CDCl3)δ7.46-7.44(m,2H),7.34-7.32 (m,3H),6.37(dt,J=15.9,5.2Hz,1H),5.99(dt,J=15.9,1.8Hz,1H), 4.29(dd,J=5.2,1.8Hz,2H),1.66(s,1H).;13C NMR(125MHz,CDCl3) δ141.7,131.5,128.3,128.2,123.2,110.5,90.2,87.2,63.1.
实施例2
Figure BDA0002181440660000081
将0.01mmol
Figure BDA0002181440660000082
0.02mmol四(3,5-二(三氟甲基)苯基)硼酸钠加入到15mlschlenck管中,氮气保护完成后,再用注射器加入0.2mmol 2-(3-(邻甲基)苯基-2-丙炔基)环氧乙烷和2m L DCE。接着,在90℃油浴下反应过夜。反应结束后,在反应液中加入两药匙柱层析硅胶(100-200目),并通过减压蒸馏除去溶剂,再通过柱色谱分离得到产物纯品(以石油醚/乙酸乙酯=5:1作为洗脱剂)。该物质为黄色液体,产率65%。
表征数据:1H NMR(500MHz,CDCl3)δ7.42(d,J=7.5Hz,1H), 7.23–7.20(m,2H),7.17–7.13(m,1H),6.36(dt,J=15.9,5.3Hz, 1H),6.03(dt,J=15.9,1.8Hz,1H),4.29(dd,J=5.3,1.8Hz, 2H),2.45(s,3H),1.63(s,1H);13C NMR(125MHz,CDCl3)δ1 41.3,140.1,131.8,129.4,128.2,125.5,123.0,110.8,91.1,89.1,63. 0,20.6.
实施例3
Figure BDA0002181440660000083
将0.004mmol
Figure BDA0002181440660000084
0.01mmol四(3,5-二(三氟甲基)苯基) 硼酸钠加入到15mlschlenck管中,氮气保护完成后,再用注射器加入0.2mmol 2-(3-(对乙基)苯基-2-丙炔基)环氧乙烷和2mL D CE。接着,在90℃油浴下反应过夜。反应结束后,在反应液中加入两药匙柱层析硅胶(100-200目),并通过减压蒸馏除去溶剂,再通过柱色谱分离得到产物纯品(以石油醚/乙酸乙酯=5:1作为洗脱剂)。该物质为黄色液体,产率56%。
表征数据1H NMR(500MHz,CDCl3)δ7.37(m,2H),7.16(m,2 H),6.34(dt,J=15.9,5.3Hz,1H),5.98(dt,J=15.8,1.8Hz,1 H),4.27(dd,J=5.3,1.8Hz,2H),2.66(q,J=7.6Hz,2H),1.67 (s,1H),1.24(t,J=7.6Hz,3H);13C NMR(125MHz,CDCl3)δ 144.6,141.3,131.5,127.9,120.3,110.7,90.4,86.6,63.0,28.8,15. 3.
实施例4
Figure BDA0002181440660000091
将0.004mmol
Figure BDA0002181440660000092
0.02mmol四(3,5-二(三氟甲基) 苯基)硼酸钠加入到15mlschlenck管中,氮气保护完成后,再用注射器加入0.2mmol 2-(3-(对甲氧基)苯基-2-丙炔基)环氧乙烷和 2mL DCE。接着,在80℃油浴下反应过夜。反应结束后,在反应液中加入两药匙柱层析硅胶(100-200目),并通过减压蒸馏除去溶剂,再通过柱色谱分离得到产物纯品(以石油醚/乙酸乙酯=5:1作为洗脱剂)。该物质为黄色液体,产率52%。
表征数据:1H NMR(500MHz,CDCl3)δ7.82(m,2H),7.37(m, 2H),6.29(dt,J=15.8,5.3Hz,1H),5.98(dt,J=15.9,1.7Hz,1 H),4.22(m,2H),3.78(s,2H),1.89(s,1H);13C NMR(125MHz, CDCl3)δ159.6,141.1,133.0,115.4,114.1,110.8,90.2,86.2,63.0, 55.3.
实施例5
Figure BDA0002181440660000101
将0.004mmol
Figure BDA0002181440660000102
0.02mmol四(3,5-二(三氟甲基)苯基)硼酸钠加入到15mlschlenck管中,氮气保护完成后,再用注射器加入0.2mmol 2-(3-(3-噻吩基)-2-丙炔基)环氧乙烷和2mL 甲苯。接着,在90℃油浴下反应过夜。反应结束后,在反应液中加入两药匙柱层析硅胶(100-200目),并通过减压蒸馏除去溶剂,再通过柱色谱分离得到产物纯品(以石油醚/乙酸乙酯=5:1作为洗脱剂)。该物质为黄色液体,产率60%。
表征数据:1H NMR(500MHz,CDCl3)δ7.43(m,1H),7.27(m, 1H),7.11(dd,J=5.0,0.8Hz,1H),6.33(dt,J=15.9,5.2Hz,1 H),5.95(dt,J=15.9,1.6Hz,1H),4.27(m,2H),1.45(t,J=6.0 Hz,1H);13C NMR(125 MHz,CDCl3):δ141.7,129.8,128.6,12 5.4,122.3,110.4,87.0,85.4,63.0。

Claims (6)

1.一种合成反式2-烯-4-炔-1-醇类化合物的方法,其特征在于:所述的方法按照如下步骤进行制备:
以式Ⅰ所示2-丙炔基环氧乙烷为起始物,在金催化剂、四(3,5-二(三氟甲基)苯基)硼酸钠、溶剂存在条件下,加热至80℃-100℃反应过夜,得到反应液经分离纯化,制备得到式Ⅱ所示反式线性2-炔-4-烯-1-醇类化合物;所述四(3,5-二(三氟甲基)苯基)硼酸钠、金催化剂与式Ⅰ所示2-丙炔基环氧乙烷的物质的量之比为
Figure FDA0003914047030000011
式Ⅰ或Ⅱ中,R为苯基、4-乙基苯基、2-甲基苯基、4-甲氧基苯基或3-噻吩基中的一种;所述的金催化剂为:
Figure FDA0003914047030000012
2.如权利要求1所述的方法,其特征在于:所述式Ⅱ所示反式线性2-炔-4-烯-1-醇类化合物为下列化合物之一:
Figure FDA0003914047030000013
3.如权利要求1所述的方法,其特征在于:所述的反应温度为90℃。
4.如权利要求1所述的方法,其特征在于:所述溶剂为二氯乙烷、甲苯或氟苯中的一种。
5.如权利要求1所述的方法,其特征在于:所述溶剂的加入量以所述式Ⅰ所示2-丙炔基环氧乙烷的物质的量计为10L/mol。
6.如权利要求1所述的方法,其特征在于:所述反应液的分离纯化为:将反应液冷却至室温后,在反应液中加入柱层析硅胶,并通过减压蒸馏除去溶剂,通过柱色谱分离,以石油醚/乙酸乙酯=5:1作为洗脱剂,收集含目标产物的洗脱液,减压蒸除溶剂得到目标产物。
CN201910797729.9A 2019-08-27 2019-08-27 一种合成反式2-烯-4-炔-1-醇类化合物的方法 Active CN110563551B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910797729.9A CN110563551B (zh) 2019-08-27 2019-08-27 一种合成反式2-烯-4-炔-1-醇类化合物的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910797729.9A CN110563551B (zh) 2019-08-27 2019-08-27 一种合成反式2-烯-4-炔-1-醇类化合物的方法

Publications (2)

Publication Number Publication Date
CN110563551A CN110563551A (zh) 2019-12-13
CN110563551B true CN110563551B (zh) 2023-01-10

Family

ID=68776417

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910797729.9A Active CN110563551B (zh) 2019-08-27 2019-08-27 一种合成反式2-烯-4-炔-1-醇类化合物的方法

Country Status (1)

Country Link
CN (1) CN110563551B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756762C1 (ru) * 2020-11-19 2021-10-05 Федеральное государственное бюджетное образовательное учреждение высшего образования "Уфимский государственный нефтяной технический университет" Способ получения этил (2E)-5-фенилпент-2-ен-4-иноата

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2237478A1 (en) * 1995-12-06 1997-06-12 David Cheshire Compounds
CN102311314A (zh) * 2011-07-06 2012-01-11 帕潘纳(北京)科技有限公司 一种法卡林醇合成方法
CN109336846A (zh) * 2018-11-16 2019-02-15 常州大学 (3z,6z)-9,10-环氧-十八碳二烯的合成方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2237478A1 (en) * 1995-12-06 1997-06-12 David Cheshire Compounds
CN102311314A (zh) * 2011-07-06 2012-01-11 帕潘纳(北京)科技有限公司 一种法卡林醇合成方法
CN109336846A (zh) * 2018-11-16 2019-02-15 常州大学 (3z,6z)-9,10-环氧-十八碳二烯的合成方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Isomerization acetylenic α-olefin oxides with the triple bond inβ position with respect to the oxide ring;Malinovskii, M. S.等;《Zhurnal Organicheskoi Khimii》;19671231;第3卷(第10期);第1792页图,第1793页第2段 *
Tertiary Amino Group in Cationic Gold Catalyst: Tethered Frustrated Lewis Pairs That Enable Ligand-Controlled Regiodivergent and Stereoselective Isomerizations of Propargylic Esters;Zhixun Wang等;《ACS Catal.》;20170412(第7期);第3676页第2栏第1段,第3678页Table 1 *

Also Published As

Publication number Publication date
CN110563551A (zh) 2019-12-13

Similar Documents

Publication Publication Date Title
CN104370755B (zh) 一种光学活性的3‑氨基丁醇和3‑氨基丁酸的制备方法
CN104292214B (zh) 艾氟康唑及其中间体的合成方法
JP5674059B2 (ja) ルテニウム錯体を含む水素移動反応用触媒及び水素移動反応物の製造方法
CN110563551B (zh) 一种合成反式2-烯-4-炔-1-醇类化合物的方法
CN113354586B (zh) 一种含有三氟甲基的吡唑啉酮类化合物制备方法
JP6054108B2 (ja) 光学活性2,3−ジヒドロファルネサールの製造方法
CN109535120B (zh) 7-取代-3,4,4,7-四氢环丁烷并香豆素-5-酮的制备方法
CN112479982A (zh) 一种手性吲哚-2,3-并八元碳环化合物的制备方法
CN109553633B (zh) 一种苯乙酸类型芳炔的制备方法
CN106946705B (zh) 一种合成(1r,2s)-二氢茉莉酮酸甲酯的方法
CN103288768B (zh) 光学纯阿莫罗芬盐酸盐的不对称合成方法
CN102344431A (zh) 一种制备奈必洛尔盐酸盐的方法
CN112592326B (zh) 手性(6z,9z)-3,4-环氧十八碳二烯的对映选择性合成方法
CN109265385B (zh) 一种手性催化剂的合成工艺
JPH0246590B2 (zh)
Yao et al. A practical approach to stereodefined cyclopropyl-substituted heteroarenes using a Suzuki-type reaction
CN111100165B (zh) 一种含双吡唑环的化合物及其中间体的制备方法
CN110437183B (zh) 一种合成呋喃类化合物的方法
CN114907404A (zh) 5-(2-(二取代膦基)苯基)-1-烷基-1h-吡唑膦配体及其制备方法和应用
JP4540197B2 (ja) (e)−3−メチル−2−シクロペンタデセノンの製造法
CN109761842B (zh) α-F-β-NHAc-羰基化合物的合成方法
Xi et al. Copper-Catalyzed Enantioselective Radical Esterification of Propargylic C–H Bonds
CN110003147B (zh) 一种多取代的3-亚苄基四氢呋喃化合物的制备方法
CN109666041A (zh) 一类二苯醚骨架的手性单膦配体HP-Phos及制备方法和应用
CN105722815B (zh) (甲基)丙烯酸苯酯的制造方法和(甲基)丙烯酸苯酯组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant